KRAS and pancreatic intraductal papillary-mucinous neoplasm: Wu et al. proposed that mutations in GNAS can provide a unique and parallel mechanism for IPMN progression, independent of the more established mechanism known to involve KRAS mutations, evidenced by tumors with GNAS mutant status lacking mutant KRAS [12] and vice versa.